Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises

AstraZeneca reported Tuesday that its BTK contender Calquence (acalabrutinib) aced a Phase III trial as a second-line therapy for chronic lymphocytic leukemia patients, allowing researchers to call it early as they position this drug for greener pastures.